FIELD: molecular biology; genetic engineering; medicine.
SUBSTANCE: present invention relates to molecular biology, genetic engineering and medicine, in particular to a bifunctional angiogenesis inhibitor. The invention also discloses a polynucleotide encoding the specified inhibitor, a vector, a host cell, a pharmaceutical composition containing the specified inhibitor, as well as a method for its preparation and application. The angiogenesis inhibitor according to the invention can be used in the preparation of a drug to reduce retinal damage in a subject with diabetes, in the preparation of a drug to inhibit the proliferation of retinal vascular endothelial cells caused by two factors VEGF and FGF or caused by high glucose levels, as well as in the preparation of a drug for the treatment of angiogenesis-related eye diseases, and angiogenesis-related eye diseases are selected from a group consisting of: age-related macular degeneration, such as dry AMD form and wet AMD form, diabetic retinopathy, such as non-proliferative DR, proliferative DR and DMO, diabetic macular edema, retinopathy of prematurity and retinal vascular occlusion.
EFFECT: present invention makes it possible to increase the biological activity and effectiveness of exposure to the targets of VEGF and FGF angiogenesis inhibitors with an increase in the storage time of the drug.
21 cl, 2 dwg, 25 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FGF-R-Fc FUSED PROTEIN AND USE THEREOF | 2012 |
|
RU2560573C2 |
| ANTIANGIOGENIC INDUCER FUSION PROTEIN AND USING IT | 2012 |
|
RU2560589C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| MOLECULES WHICH BIND LIGANDS AND USE THEREOF | 2014 |
|
RU2699007C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| RECOMBINANT VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) SECRETING Escherichia coli BL21 (pVEGF-A165) CELL STRAIN | 2008 |
|
RU2395568C2 |
| POLYPEPTIDES DERIVED FROM TRYPTOPHANYL-TRNA-SYNTHETASE AND USES THEREOF IN CONTROLLING OF VASCULARISATION | 2002 |
|
RU2297425C2 |
| HUMAN PROTEIN TYROSINE PHOSPHATASE BETA BINDING ANTIBODIES (HPTPBETA), AND USE THEREOF | 2007 |
|
RU2494108C2 |
